EE181 An Economic Model to Estimate Costs of Cytokine Release Syndrome (CRS) and Neurological Events (NE) Among Patients Treated with Lisocabtagene Maraleucel (LISO-CEL) or Axicabtagene Ciloleucel (AXI-CEL) for Second-LINE (2L) Treatment of Large B-Cell Lymphoma

Chimeric antigen receptor (CAR) T cell therapies have demonstrated good clinical responses in populations that historically been difficult to treat; however, they are associated with potentially severe adverse events, including CRS and NEs. An economic model was created estimate total weighted costs of NEs for 2L treatment transplant-eligible relapsed/refractory large B-cell non-Hodgkin lymphoma treated liso-cel axi-cel based on rates reported the TRANSFORM (NCT03575351) ZUMA-7 (NCT03391466) studies. A decision tree developed using NE from a health care system perspective 2021 United States dollars. Cost inputs were micro-costing analysis TRANSFORM, assumed cost or management would not differ across therapies. probabilistic sensitivity conducted Monte Carlo simulation methods address uncertainty surrounding key inputs. scenario also assess each CAR therapy commercial payer perspective. The overall per-patient average $3951 (liso-cel) $15,084 (axi-cel). Per-patient per event $1850 $4857 $2101 $10,228 In analysis, $5621 $21,529 Reductions estimated compared axi-cel, owing lower rates, $3007 $8127 respectively, model; difference $11,133 (74% liso-cel). These highlight importance differentiated safety profiles between